Optimizing the treatment of hypothyroidism

IF 3.7 3区医学 Q2 CHEMISTRY, MEDICINAL

Chemical Research in Toxicology Pub Date : 2024-04-29 DOI:10.1038/s41574-024-00989-7

Antonio C. Bianco, Peter N. Taylor

引用次数: 0

Abstract

Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.

查看原文本刊更多论文

优化甲状腺功能减退症的治疗

每日服用左甲状腺素（LT4）是治疗甲状腺功能减退症的标准方法；然而，少数患者会出现甲状腺功能减退症的残留症状。指南》指出，在治疗或排除其他疾病后，可尝试使用 LT4 和甲状腺素（LT3）进行试验。即便如此，目前对甲减的治疗仍有可能达不到最佳效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemical Research in Toxicology 医学-毒理学

CiteScore

7.90

自引率

7.30%

发文量

215

审稿时长

3.5 months

期刊介绍： Chemical Research in Toxicology publishes Articles, Rapid Reports, Chemical Profiles, Reviews, Perspectives, Letters to the Editor, and ToxWatch on a wide range of topics in Toxicology that inform a chemical and molecular understanding and capacity to predict biological outcomes on the basis of structures and processes. The overarching goal of activities reported in the Journal are to provide knowledge and innovative approaches needed to promote intelligent solutions for human safety and ecosystem preservation. The journal emphasizes insight concerning mechanisms of toxicity over phenomenological observations. It upholds rigorous chemical, physical and mathematical standards for characterization and application of modern techniques.